Table 1 Demographic characteristics of the participants (FAS)

From: Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

 

1–3 months

4–6 months

≥6 months

 

NVSI-06-07 (N = 301)

BBIBP-CorV (N = 299)

P value

NVSI-06-07 (N = 300)

BBIBP-CorV (N = 300)

P value

NVSI-06-07 (N = 298)

BBIBP-CorV (N = 302)

P value

Age (yrs)

Mean (SD)

33.30 (8.88)

33.43 (9.38)

0.8642

34.10 (7.89)

34.53 (8.59)

0.5159

35.48 (9.53)

36.12 (9.27)

0.4036

Median

31.88

32.50

 

33.37

33.72

 

34.08

34.72

 

Min, Max

19.2, 65.4

18.0, 70.8

 

20.6, 61.8

18.9, 63.7

 

18.4, 63.7

18.2, 69.7

 

Age group, n(%)

  

0.5519

  

0.3157

  

0.9830

18–59 yrs

296 (98.34)

292 (97.66)

 

299 (99.67)

297 (99.00)

 

293 (98.32)

297 (98.34)

 

≥60 yrs

5 (1.66)

7 (2.34)

 

1 (0.33)

3 (1.00)

 

5 (1.68)

5 (1.66)

 

Sex, n(%)

  

0.6146

  

0.5026

  

0.3923

Male

261 (86.71)

255 (85.28)

 

283 (94.33)

279 (93.00)

 

258 (86.58)

254 (84.11)

 

Female

40 (13.29)

44 (14.72)

 

17 (5.67)

21 (7.00)

 

40 (13.42)

48 (15.89)

 

Height (cm)

Mean (SD)

167.52 (7.87)

167.61 (8.99)

0.8938

169.93 (7.97)

169.17 (7.79)

0.2389

170.51 (8.25)

169.47 (8.89)

0.1400

Median

168.00

168.00

 

170.00

169.00

 

171.00

171.00

 

Min, Max

147.00, 190.00

125.00, 191.00

 

110.00, 187.00

143.00, 189.00

 

143.00, 190.50

141.00, 192.00

 

Weight (kg)

Mean (SD)

71.02 (14.22)

71.96 (14.17)

0.4165

76.10 (13.27)

74.11 (13.22)

0.0665

77.12 (15.56)

76.46 (14.41)

0.5894

Median

70.00

70.70

 

75.00

73.00

 

76.00

75.50

 

Min, Max

42.00, 133.00

44.10, 126.00

 

46.80, 119.00

43.00, 128.00

 

43.50, 132.70

43.00, 127.00

 

BMI (kg/m2)

Mean (SD)

25.27 (4.56)

25.62 (4.72)

0.3562

26.37 (4.60)

25.88 (4.22)

0.1807

26.45 (4.59)

26.54 (4.22)

0.7905

Median

24.77

25.28

 

26.28

25.68

 

26.17

26.26

 

Min, Max

16.53, 45.44

17.06, 49.28

 

17.30, 67.77

15.47, 43.03

 

16.14, 43.14

17.01, 41.95